NEXGEL (NXGL) said Monday it is expanding its collaboration with European consumer health company STADA Arzneimittel to launch new digestive enzyme formulas and products for scars and stretch marks.
As part of the deal, STADA will provide NEXGEL with $1 million in non-dilutive funding to support product launches and marketing efforts, the company said.
Shares of NEXGEL were down 1.5% in recent Monday trading.
Price: 2.65, Change: -0.04, Percent Change: -1.48
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。